LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

2012: Collaborative patient partnership delivers first treatment approved in Europe for genetic disease, Alkaptonuria (AKU)

16/06/2021

Nominated by: Sobi, Swedish Orphan Biovitrum 

Organisations in nomination: DevelopAKUre Consortium

AKU is a serious, multi-system disorder affecting approximately 1 in 250,000 people, first described as early as 1902 by Archibald Edward Garrod.

Morbidity is caused by inability to metabolise the amino acid tyrosine, resulting in increased levels homogentisic acid (HGA). This leads to early onset, severe arthritis, with disability and significant need of health care interventions such as multiple joint replacements as a result.  Patients report constant pain, difficulty with daily living activities, poor sleep, depression, poor quality of life, and unemployment and isolation is common.

In 2012, a European Union project called DevelopAKUre (FP7, Grant number 304985) brought together scientists, patient organisations, regulatory and clinical trial experts, to improve the understanding of alkaptonuria, and deliver a clinical development programme for the first ever treatment (Orfadin®, nitisinone).  The collaborative project was a paradigm-shift for joint efforts across multiple parties as a model for rare disease advances for patients.

For the first time, studies identified the appropriate dose needed in AKU as well as demonstrating improved clinical parameters and Orfadin® was approved by the EMA in 2020.

The unique consortium further provided clinical development innovation in rare disease, sharing lessons learned and best practice with the wider community on collaboration across academia-patients-industry.

https://europabio25.org/wp-content/uploads/Nick-AKU-EuropaBio-videos-1-2_Twitter.mp4

References:

  • FP7 project: Clinical Development of Nitisinone for Alkaptonuria
  • Efficacy and safety of once-daily nitisnone for patients with alkaptonuria 5SONIA 2): https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30228-X/fulltext
  • First treatment for rare metabolic disorder alkaptonuria: https://www.ema.europa.eu/en/news/first-treatment-rare-metabolic-disorder-alkaptonuria
Share
Alexandra Simionca
Alexandra Simionca
EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.